ABHD17C: A Non-Code RNA Molecule as A Potential Drug Target (G58489)

Target Name: ABHD17C

NCBI ID: G58489

ABHD17C

ABHD17C: A Non-Code RNA Molecule as A Potential Drug Target

ABHD17C (FAM108C1) is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study and potentially develop new treatments.

ABHD17C is a small molecule RNA that is approximately 200 amino acids long. It is derived from the protein FAM108C1, which is a key regulator of the immune response. The RNA molecule is expressed in a variety of tissues and cells in the body and is involved in the regulation of gene expression.

One of the key features of ABHD17C is its ability to interact with other molecules and proteins. This interaction is important for its function as a drug target. By interacting with specific proteins, ABHD17C can regulate the activity of those proteins and potentially disrupt their function in the development of various diseases.

One of the ways that ABHD17C is thought to work is by regulating the activity of immune cells. Immune cells, such as T cells and B cells, are important for fighting off infections and cancer. However, sometimes their activity can be too strong or become imbalanced, leading to the development of diseases such as cancer.

ABHD17C is thought to help regulate the activity of immune cells by controlling the production of specific proteins. For example, studies have shown that ABHD17C can inhibit the production of T cells, which are a critical part of the immune system. This can help to reduce the overall activity of the immune system and prevent it from becoming too strong or imbalanced.

Another way that ABHD17C is thought to work is by regulating the production of mRNA, which is the language of the immune system. MRNA is the material that instructions the immune cells to produce the specific proteins that they need to fight off infections and cancer.

ABHD17C is thought to help regulate the production of mRNA by controlling the levels of certain genes. For example, studies have shown that ABHD17C can interact with the protein Myb, which is involved in the regulation of mRNA production. This interaction can help to regulate the levels of Myb in the cell, which in turn can affect the production of mRNA.

In addition to its role in regulating immune cells and mRNA production, ABHD17C is also thought to be involved in the regulation of cell signaling pathways. These pathways are the channels through which cells communicate with each other and with the surrounding environment.

ABHD17C is thought to be involved in the regulation of several different signaling pathways, including the PI3K/Akt signaling pathway and the NF-kappa-B signaling pathway. These pathways are important for the regulation of various cellular processes, including cell growth, differentiation, and inflammation.

Finally, ABHD17C is also thought to be involved in the regulation of cellular processes that are important for the development of diseases. For example, studies have shown that ABHD17C is involved in the regulation of the development of cancer, and that its expression is often decreased in cancer cells.

In conclusion, ABHD17C is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) for the treatment of various diseases. Its unique structure and function have made it an attractive target for researchers to study and potentially develop new treatments. Further research is needed to fully understand the role of ABHD17C in the regulation of immune cells, mRNA production, cell signaling pathways, and the development of diseases.

Protein Name: Abhydrolase Domain Containing 17C, Depalmitoylase

Functions: Hydrolyzes fatty acids from S-acylated cysteine residues in proteins. Has depalmitoylating activity towards NRAS and DLG4/PSD95

The "ABHD17C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABHD17C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets